An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome

This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.

Inclusion Criteria:

• Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.

Exclusion Criteria:

• Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.